期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Casein kinase 2 interacts with and phosphorylates ataxin-3 被引量:3
1
作者 陶瑞松 费尔康 +2 位作者 应征 王洪枫 王光辉 《Neuroscience Bulletin》 SCIE CAS CSCD 2008年第5期271-277,共7页
Objective Machado-Joseph disease (MJD)/Spinocerebellar ataxia type 3 (SCA3) is an autosomal dominant neurodegenerative disorder caused by an expansion of polyglutamine tract near the C-terminus of the MJD1 gene pr... Objective Machado-Joseph disease (MJD)/Spinocerebellar ataxia type 3 (SCA3) is an autosomal dominant neurodegenerative disorder caused by an expansion of polyglutamine tract near the C-terminus of the MJD1 gene product, ataxin-3. The precise mechanism of the MJD/SCA3 pathogenesis remains unclear. A growing body of evidence demonstrates that phosphorylation plays an important role in the pathogenesis of many neurodegenerative diseases. However, few kinases are known to phosphorylate ataxin-3. The present study is to explore whether ataxin-3 is a substrate of casein kinase 2 (CK2). Methods The interaction between ataxin-3 and CK2 was identified by glutathione S-transferase (GST) pull-down assay and co-immunoprecipition assay. The phosphorylation of ataxin-3 by CK2 was measured by in vitro phosphorylation assays. Results (1) Both wild type and expanded ataxin-3 interacted with CK2α and CK2β in vitro. (2) In 293 cells, both wild type and expanded ataxin-3 interacted with CK2β, but not CK2α. (3) CK2 phosphorylated wild type and expanded ataxin-3. Conclusion Ataxin-3 is a substrate of protein kinase CK2. 展开更多
关键词 Machado-Joseph disease/spinocerebellar ataxia type 3 ATAXIN-3 casein kinase 2 PHOSPHORYLATION
下载PDF
西格列汀及胰高血糖素样肽1对脐静脉内皮细胞铁代谢相关基因的调控作用 被引量:3
2
作者 李莉 金军华 +5 位作者 邹丽辉 张恩毅 张俊华 黄薇 潘琦 肖飞 《中华糖尿病杂志》 CAS CSCD 2017年第5期292-297,共6页
目的 观察西格列汀及胰高血糖素样肽1(GLP-1)对正常糖浓度(正糖)及高糖条件下人脐静脉内皮细胞(HUVECs)铁代谢相关共济蛋白(FXN)及顺乌头酸梅1(ACO1)蛋白表达的影响.方法 用西格列汀(1μmol/L)和(或)GLP-1(100 nmol/L)... 目的 观察西格列汀及胰高血糖素样肽1(GLP-1)对正常糖浓度(正糖)及高糖条件下人脐静脉内皮细胞(HUVECs)铁代谢相关共济蛋白(FXN)及顺乌头酸梅1(ACO1)蛋白表达的影响.方法 用西格列汀(1μmol/L)和(或)GLP-1(100 nmol/L)处理HUVECs,正糖(5.5 mmol/L)及高糖(30.0 mmol/L)状态下分别设相应对照组、GLP-1处理组、西格列汀处理组以及GLP-1+西格列汀联合处理组.检测药物对正常状态下HUVECs细胞增殖的影响,用实时定量逆转录PCR和Western blotting法分别于24 h及48 h后检测HUVECs内FXN和ACO1的mRNA及蛋白表达水平.多组间比较采用单因素方差分析,两组间比较使用Bonferroni检验(满足方差齐性检验时)或Dunnett T3检验(不满足方差齐性检验时).结果 (1)正糖下经西格列汀和(或)GLP-1处理24 h后,与对照组(表达水平设为1)相比,各组的HUVECs细胞增殖水平均无明显变化(分别为0.99±0.04、1.07±0.08、1.06±0.05,F=4.059,均P〉0.05);而各加药组的FXN mRNA表达均呈下降趋势,其中,西格列汀+GLP-1组FXN的mRNA表达水平降低为0.68±0.18(t=3.59,P〈0.05);西格列汀单独或联合GLP-1组ACO1的mRNA表达水平也明显降低(分别为0.49±0.13、0.59±0.15,F=10.802,均P〈0.05);各加药组的FXN及ACO1的蛋白水平均低于对照组,但差异无统计学意义(均P〉0.05).(2)高糖下经西格列汀和(或)GLP-1处理48 h后,与对照组(表达水平设为1)相比,西格列汀+GLP-1组FXN mRNA表达升高(1.75±0.26,t=-5.71,P〈0.05);但各组的ACO1 mRNA表达变化均不明显且差异无统计学意义(均P〉0.05).结论 西格列汀和GLP-1可在不影响正常状态内皮细胞增殖的条件下,通过调节正常或高糖状态下HUVECs中FXN及ACO1的表达水平影响细胞内的铁代谢. 展开更多
关键词 西格列汀 胰高血糖素样肽1 共济蛋白 顺乌头酸梅1 人脐静脉内皮细胞
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部